|Home page  | Editorial   | Journal  |  Guidelines to authors |  Contact  |

Acta Medica Medianae
Vol. 47, No3 , October, 2008
UDK 61
YU ISSN 0365-4478


Correspondence to:
Marko Folić

Služba za kliničku i eksperimentalnu farmakologiju Kliničkog centra

Zmaj Jovina 30

34000 Kragujevac, Srbija

E-mail: markof@medf.kg.ac.yu







Copyright 2008 by Faculty  of Medicine, University of Nis

Review article




Marko Folic, Nevena Folic, Mirjana Varjacic, Mihajlo Jakovljevic and Slobodan Jankovic



Hypertension in pregnancy is associated with increased maternal and fetal mortality and morbidity. About 8 % of all pregnancies are complicated with hypertensive disorders. There is  concordance that severe hypertension should be treated without delay to reduce maternal risks of acute cerebrovascular complications. Intravenous labetalol and oral nifedipine are as effective as intravenous hydralazine in control of severe hypertension, with less adverse effects. Still, there is no consensus as to whether mild-to-moderate hypertension in pregnancy should be treated, considering that there are no definitive conclusions which can be made about the relative maternal or perinatal benefits/risks of antihypertensive treatment. Considering their safe usage during pregnancy, methyldopa, labetalol and nifedipine are commonly used blood-pressure lowering drugs for pregnant women with hypertension. The cardio-selective β- blocker atenolol should be avoided in pregnancy, because it has been associated with lower birth weights and fetal growth impairment. ACE inhibitors and angiotensin receptor blockers are contraindicated in pregnancy. Acta Medica Medianae 2008;47(3):65-72.


Key words: antihypertensive drugs, hypertensive disorders, pregnancy

Fulll text